Matrix metalloproteinase (MMP)-2 and MMP-9 polymorphisms and haplotypes as disease biomarkers

Biomarkers

Volumn 17, Issue 3, 2012, Pages 286-288

  Luizon, Marcelo Rizzatti ^a   De Almeida Belo, Vanessa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cancer; Cardiovascular diseases; Genetic polymorphisms; Haplotypes; Matrix metalloproteinase 2 gene; Matrix metalloproteinase 9 gene

Indexed keywords

GELATINASE A; GELATINASE B;

ARTICLE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HEAD AND NECK CARCINOMA; HYPERTENSION; MOUTH DISEASE; MULTIPLE SCLEROSIS; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; ORAL SUBMUCOUS FIBROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 84860366270     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.657685     Document Type: Article

References (18)

1. Belo VA, Souza-Costa DC, Luizon MR, Lanna CM, Carneiro PC, Izidoro-Toledo TC, Ferraz KC, Tanus-Santos JE. (2012). Matrix metalloproteinase-9 genetic variations affect MMP-9 levels in obese children. Int J Obes (Lond) 36:69-75.
2. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L; AtheroGene Investigators. (2003). Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107:1579-1585. (Pubitemid 36397324)
3. Chaudhary AK, Pandya S, Mehrotra R, Singh M, Singh M. (2011). Role of functional polymorphism of matrix metalloproteinase-2 (-1306 C/T and -168 G/T) and MMP-9 (-1562 C/T) promoter in oral submucous fibrosis and head and neck squamous cell carcinoma in an Indian population. Biomarkers 16:577-586.
4. Crawford DC, Nickerson DA. (2005). Definition and clinical importance of haplotypes. Annu Rev Med 56:303-320. (Pubitemid 40299785)
5. Demacq C, de Souza AP, Machado AA, Gerlach RF, Tanus-Santos JE. (2006). Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin Chim Acta 365:183-187. (Pubitemid 43196436)
6. Demacq C, Vasconcellos VB, Marcaccini AM, Gerlach RF, Machado AA, Tanus-Santos JE. (2009). A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients. Pharmacogenomics J 9:265-273.
7. Demacq C, Vasconcellos VB, Marcaccini AM, Gerlach RF, Silva WA Jr, Tanus-Santos JE. (2008). Functional polymorphisms in the promoter of the matrix metalloproteinase-9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects. Clin Chem Lab Med 46:57-63.
8. Fernandes KS, Brum DG, Sandrim VC, Guerreiro CT, Barreira AA, Tanus-Santos JE. (2009). Matrix metalloproteinase-9 genotypes and haplotypes are associated with multiple sclerosis and with the degree of disability of the disease. J Neuroimmunol 214:128-131.
9. Lacchini R, Jacob-Ferreira AL, Luizon MR, Coeli FB, Izidoro-Toledo TC, Gasparini S, Ferreira-Sae MC, Schreiber R, Nadruz W, Jr., Tanus- Santos JE. (2010a). Matrix metalloproteinase 9 gene haplotypes affect left ventricular hypertrophy in hypertensive patients. Clin Chim Acta 411:1940-1944.
10. Lacchini R, Jacob-Ferreira AL, Luizon MR, Gasparini S, Ferreira-Sae MC, Schreiber R, Nadruz W, Jr., Tanus-Santos JE. (2011). Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients. J Hum Hypertens. DOI:10.1038/jhh.2011.8.
11. Lacchini R, Metzger IF, Luizon M, Ishizawa M, Tanus-Santos JE. (2010b). Interethnic differences in the distribution of matrix metalloproteinases genetic polymorphisms are consistent with interethnic differences in disease prevalence. DNA Cell Biol 29:649-655.
12. Luizon MR, Sandrim VC. (2011). Importance of haplotype analysis in association studies considering VEGF promoter polymorphisms. Clin Biochem 44:747; author reply 748.
13. Metzger IF, Luizon MR, Lacchini R, Tanus-Santos JE. (2011). Genetic Variants in Matrix Metalloproteinase-9 Gene Modify Metalloproteinase-9 Levels in Black Subjects. DNA Cell Biol. DOI:10.1089/dna.2011.1388.
14. Palei AC, Sandrim VC, Duarte G, Cavalli RC, Gerlach RF, Tanus-Santos JE. (2010). Matrix metalloproteinase (MMP)-9 genotypes and haplotypes in preeclampsia and gestational hypertension. Clin Chim Acta 411:874-877.
15. Sandrim VC, Tanus-Santos JE. (2007). Haplotype analysis can provide improved clinical information than single genotype analysis. Thromb Res 120:779. (Pubitemid 47268038)
16. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D. (2004). Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 64:7622-7628. (Pubitemid 39372109)
17. Zhou G, Zhai Y, Cui Y, Qiu W, Yang H, Zhang X, Dong X, He Y, Yao K, Zhang H, Peng Y, Yuan X, Zhi L, Zhang X, He F. (2007). Functional polymorphisms and haplotypes in the promoter of the MMP2 gene are associated with risk of nasopharyngeal carcinoma. Hum Mutat 28:1091-1097. (Pubitemid 350036913)
18. Zhou Y, Yu C, Miao X, Wang Y, Tan W, Sun T, Zhang X, Xiong P, Lin D. (2005). Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis 26:1117-1121. (Pubitemid 41214305)